Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH

Treatment of Nonalcoholic fatty liver disease (NAFLD) constitutes an unmet clinical need owing to the relatively limited efficacy of both novel and readily available metabolic medications, thus warranting pathobiological investigations on the mechanisms of single or combination regimens. In this con...

Full description

Saved in:
Bibliographic Details
Published in:J Endocr Soc
Main Authors: Perakakis, Nikolaos, Stefanakis, Konstantinos, Feigh, Michael, Veidal, Sanne S, Mantzoros, Christos S
Format: Artigo
Language:Inglês
Published: Oxford University Press 2021
Subjects:
Cardiovascular Endocrinology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089912/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.642
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items